Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, and Glyco-biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Others), and Application (Diagnostics, Drug Discovery and Development, Prognostics,Risk Assessment, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
The global cancer biomarkers market was valued at $10,944.08 million in 2019, and is projected to reach $26,979.50 million by 2027, registering a CAGR of 11.8% from 2020 to 2027.
Cancer biomarkers are traceable substances or molecules that indicate the existence of cancerous cells in the body. The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach to obtain rapid results for treatment. There are various types of biomarkers such as proteins, peptides, antibodies, and nucleic acids. Presence of these biomarkers in tissues, urine, serum, blood, and other body fluids indicate an abnormal process or a disease. Various such biomarkers for cancer indications have been studied and are being used for diagnostics, prognostics, personalized medicines, and surrogate endpoints. The identification of different types of biomarkers is an integral part of various industries such as healthcare and pharmaceuticals.
The global cancer biomarkers market is expected to witness a significant growth during the forecast period due to increase in prevalence of various types of cancers such as breast, prostate, and lung cancer. In addition, surge in importance of biological & targeted drug therapies, technological advancements, accuracy, and reliability of cancer biomarkers also contribute toward the growth of the market. Moreover, increase in investments from governments and public & private sector toward R&D for cancer diagnostics have a positive impact on the market. However, high cost of drug development, threat of failure associated with cancer treatment, and unregulated government regulations and reimbursement policies hamper the market growth. In contrast, advancements of cancer research and significant unmet need for cancer diagnosis are anticipated to provide new opportunities for the cancer biomarkers market.
The market is segmented on the basis of profiling technology, biomolecule, cancer type, application, and region. By profiling technology, the market is bifurcated into omic technologies, imaging technologies, immunoassays, and cytogenetics-based tests. On the basis of biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By biomolecule, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By cancer type, the market is segmented as breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. Based on application, the market is segmented across diagnostics, drug discovery and development, prognostics, risk assessment, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
By Profiling Technology
Cancer biomarkers are traceable substances or molecules that indicate the existence of cancerous cells in the body. The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach to obtain rapid results for treatment. There are various types of biomarkers such as proteins, peptides, antibodies, and nucleic acids. Presence of these biomarkers in tissues, urine, serum, blood, and other body fluids indicate an abnormal process or a disease. Various such biomarkers for cancer indications have been studied and are being used for diagnostics, prognostics, personalized medicines, and surrogate endpoints. The identification of different types of biomarkers is an integral part of various industries such as healthcare and pharmaceuticals.
The global cancer biomarkers market is expected to witness a significant growth during the forecast period due to increase in prevalence of various types of cancers such as breast, prostate, and lung cancer. In addition, surge in importance of biological & targeted drug therapies, technological advancements, accuracy, and reliability of cancer biomarkers also contribute toward the growth of the market. Moreover, increase in investments from governments and public & private sector toward R&D for cancer diagnostics have a positive impact on the market. However, high cost of drug development, threat of failure associated with cancer treatment, and unregulated government regulations and reimbursement policies hamper the market growth. In contrast, advancements of cancer research and significant unmet need for cancer diagnosis are anticipated to provide new opportunities for the cancer biomarkers market.
The market is segmented on the basis of profiling technology, biomolecule, cancer type, application, and region. By profiling technology, the market is bifurcated into omic technologies, imaging technologies, immunoassays, and cytogenetics-based tests. On the basis of biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By biomolecule, the market is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By cancer type, the market is segmented as breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. Based on application, the market is segmented across diagnostics, drug discovery and development, prognostics, risk assessment, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
By Profiling Technology
- Omic Technologies
- Imaging Technologies
- Immunoassays
- Cytogenetics-based Tests
- Genetic Biomarkers
- Protein Biomarkers
- Glyco-biomarkers
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Others
- Diagnostics
- Drug Discovery and Development
- Prognostics
- Risk Assessment
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- United Arab Emirates
- Rest of LAMEA
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Bristol-Myers Squibb Compnay
- Exact Sciences Corporation
- F.Hoffmann-La Roche Ltd.
- Merck KGaA
- PerkinElmer, Inc.
- Qiagen N.V.
- Siemens AG
- Thermo Fisher Scientific, Inc.
CHAPTER 1:INTRODUCTION40
1.1.Report description40
1.2.Key benefits for stakeholders41
1.3.Key market segments43
1.3.1.List of key players profiled in the report45
1.4.Research methodology46
1.4.1.Secondary research48
1.4.2.Primary research48
1.4.3.Analyst tools and models49
CHAPTER 2:EXECUTIVE SUMMARY50
2.1.Key findings of the study52
2.2.CXO perspective53
CHAPTER 3:MARKET OVERVIEW54
3.1.Market definition and scope54
3.2.Biomarker Diagnosis vs. Conventional Diagnosis56
3.3.Key findings57
3.3.1.Top investment pockets57
3.4.Porter's five forces analysis59
3.4.1.Bargaining power of buyers59
3.4.2.Bargaining power of suppliers60
3.4.3.Thereat of new entrants61
3.4.4.Threat of substitutes62
3.4.5.Intensity of competitive rivalry63
3.5.Top player positioning, 201964
3.6.Market dynamics65
3.6.1.Drivers65
3.6.1.1.Rise in incidence and prevalence of various cancer types65
3.6.1.2.Growth in importance of biological and targeted drug therapies67
3.6.1.3.Increase in acquisitions and collaborations69
3.6.1.4.Increase in technological advancements70
3.6.1.5.High accuracy and reliability70
3.6.1.6.Rise in investment from government, public, and private sectors70
3.6.1.7.Increase in clinical trials71
3.6.1.8.Growth in popularity of personalized medicine and companion diagnostics71
3.6.2.Restraint72
3.6.2.1.High cost of drug development and threat of failure72
3.6.2.2.Unregulated government regulation and reimbursement policies72
3.6.2.3.Adverse effects of cancer drug therapy73
3.6.3.Opportunity73
3.6.3.1.Advancement of cancer drugs research73
3.6.3.2.Increased focus towards advanced treatment protocols74
3.6.3.3.Significant unmet need in cancer diagnosis74
3.6.3.4.Increased awareness to reduce healthcare costs74
3.6.3.5.Opportunities in emerging economies75
3.6.4.Impact Analyses75
3.7.PATENT ANALYSIS76
3.8.Clinical Trials Analysis78
CHAPTER 4:CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY79
4.1.Overview79
4.1.1.Market size and forecast, by profiling technologies80
4.2.OMIC TECHNOLOGIES82
4.2.1.Key market trends and growth opportunities82
4.2.2.Market size and forecast, by region83
4.2.3.Market analysis, by country84
4.2.4.Market size and forecast, by type85
4.2.5.Genomics86
4.2.5.1.Market Size and forecast87
4.2.5.2.Next Generation Sequencing (NGS)88
4.2.5.3.Microarray89
4.2.5.4.Polymerase chain reaction (PCR)89
4.2.6.Proteomics90
4.2.6.1.Market size and forecast90
4.2.6.2.Mass spectrometry92
4.2.6.3.2D gel electrophoresis92
4.2.6.4.Protein microarray technology93
4.2.6.5.Antibody array technology94
4.2.6.6.Peptide array technology94
4.2.7.Other omic technologies95
4.2.7.1.Market size and forecast95
4.2.7.2.Metabolomics96
4.2.7.3.Glycomics97
4.3.IMAGING TECHNOLOGIES97
4.3.1.Key market trends and growth opportunities97
4.3.2.Market size and forecast, by region98
4.3.3.Market analysis, by countries99
4.3.4.Market size and forecast, by type100
4.3.5.Magnetic resonance imaging (MRI)101
4.3.5.1.Market size and forecast102
4.3.6.Positron emission tomography (PET)103
4.3.6.1.Market size and forecast103
4.3.7.Computed tomography (CT)104
4.3.7.1.Market size and forecast105
4.3.8.Mammography105
4.3.8.1.Market size and forecast106
4.3.9.Ultrasound107
4.3.9.1.Market size and forecast107
4.4.IMMUNOASSAYS108
4.4.1.Key market trends and growth opportunities109
4.4.2.Market size and forecast, by region109
4.4.3.Market analysis, by country110
4.4.4.Market size and forecast, by type112
4.4.5.Immunohistochemistry (IHC) tests113
4.4.5.1.Market size and forecast113
4.4.6.Enzyme-linked immunosorbent assay (ELISA)114
4.4.6.1.Market size and forecast114
4.4.7.Flow cytometry115
4.4.7.1.Market size and forecast116
4.5.CYTOGENETICS-BASED TESTS117
4.5.1.Key market trends and growth opportunities117
4.5.2.Market size and forecast, by region118
4.5.3.Market analysis, by country119
4.5.4.Market size and forecast, by type120
4.5.5.In-situ hybridization121
4.5.5.1.Market size and forecast121
4.5.6.Others122
4.5.6.1.Market size and forecast122
CHAPTER 5:CANCER BIOMARKERS MARKET, BY BIOMOLECULE124
5.1.Overview124
5.1.1.Market size and forecast125
5.2.Genetic Biomarkers126
5.2.1.Market size and forecast, by region128
5.2.2.Market analysis, by country129
5.3.Protein Biomarkers130
5.3.1.Market size and forecast, by region130
5.3.2.Market analysis, by country131
5.4.Glyco-Biomarkers133
5.4.1.Market size and forecast, by region134
5.4.2.Market analysis, by country135@CHAPTER 6:CANCER BIOSENSORS MARKET, BY CANCER TYPE136
6.1.Overview136
6.1.1.Market size and forecast137
6.2.Breast Cancer138
6.2.1.Market size and forecast, by region139
6.2.2.Market analysis, by country140
6.3.Lung Cancer141
6.3.1.Market size and forecast, by region141
6.3.2.Market analysis, by country142
6.4.Colorectal cancer143
6.4.1.Market size and forecast, by region144
6.4.2.Market analysis, by country145
6.5.Prostate cancer146
6.5.1.Market size and forecast, by region147
6.5.2.Market analysis, by country148
6.6.Stomach cancer149
6.6.1.Market size and forecast, by region150
6.6.2.Market analysis, by country150
6.7.Others152
6.7.1.Market size and forecast, by region152
6.7.2.Market analysis, by country153
CHAPTER 7:CANCER BIOMARKER MARKET, BY APPLICATION155
7.1.Overview155
7.1.1.Market size and forecast155
7.2.Diagnostics157
7.2.1.Market size and forecast, by region158
7.2.2.Market analysis, by country159
7.3.Drug Discovery and Development160
7.3.1.Market size and forecast, by region161
7.3.2.Market analysis, by country162
7.4.Prognostics163
7.4.1.Market size and forecast, by region164
7.4.2.Market analysis, by country164
7.5.Risk Assessment166
7.5.1.Market size and forecast, by region166
7.5.2.Market analysis, by country167
7.6.Others168
7.6.1.Market size and forecast, by region169
7.6.2.Market analysis, by country170
CHAPTER 8:CANCER BIOMARKERS MARKET, BY REGION172
8.1.Overview172
8.1.1.Market size and forecast173
8.2.North America174
8.2.1.Key market trends and opportunities174
8.2.2.Market analysis by country175
8.2.2.1.U.S.176
8.2.2.1.1.U.S. market size and forecast, by profiling technologies176
8.2.2.1.2.U.S. market size and forecast, by biomolecules177
8.2.2.1.3.U.S. market size and forecast, by cancer type178
8.2.2.1.4.U.S. market size and forecast, by application179
8.2.2.2.Canada180
8.2.2.2.1.Canada market size and forecast, by profiling technologies180
8.2.2.2.2.Canada market size and forecast, by biomolecules182
8.2.2.2.3.Canada market size and forecast, by cancer type183
8.2.2.2.4.Canada market size and forecast, by application184
8.2.2.3.Mexico185
8.2.2.3.1.Mexico market size and forecast, by profiling technologies185
8.2.2.3.2.Mexico market size and forecast, by biomolecules187
8.2.2.3.3.Mexico market size and forecast, by cancer type188
8.2.2.3.4.Mexico market size and forecast, by application189
8.2.3.North America market size and forecast, by profiling technologies190
8.2.4.North America market size and forecast, by biomolecules191
8.2.5.North America market size and forecast, by cancer type192
8.2.6.North America market size and forecast, by application193
8.3.Europe194
8.3.1.Key market trends and opportunities194
8.3.2.Market analysis by country195
8.3.2.1.Germany197
8.3.2.1.1.Germany market size and forecast, by profiling technologies197
8.3.2.1.2.Germany market size and forecast, by biomolecules199
8.3.2.1.3.Germany market size and forecast, by cancer type200
8.3.2.1.4.Germany market size and forecast, by application201
8.3.2.2.France202
8.3.2.2.1.France market size and forecast, by profiling technologies202
8.3.2.2.2.France market size and forecast, by biomolecules204
8.3.2.2.3.France market size and forecast, by cancer type205
8.3.2.2.4.France market size and forecast, by application206
8.3.2.3.UK207
8.3.2.3.1.UK market size and forecast, by profiling technologies207
8.3.2.3.2.UK market size and forecast, by biomolecules208
8.3.2.3.3.UK market size and forecast, by cancer type209
8.3.2.3.4.UK market size and forecast, by application210
8.3.2.4.Italy211
8.3.2.4.1.Italy market size and forecast, by profiling technologies211
8.3.2.4.2.Italy market size and forecast, by biomolecules212
8.3.2.4.3.Italy market size and forecast, by cancer type213
8.3.2.4.4.Italy market size and forecast, by application214
8.3.2.5.Russia215
8.3.2.5.1.Russia market size and forecast, by profiling technologies215
8.3.2.5.2.Russia market size and forecast, by biomolecules217
8.3.2.5.3.Russia market size and forecast, by cancer type218
8.3.2.5.4.Russia market size and forecast, by application219
8.3.2.6.Rest of Europe220
8.3.2.6.1.Rest of Europe market size and forecast, by profiling technologies220
8.3.2.6.2.Rest of Europe market size and forecast, by biomolecules222
8.3.2.6.3.Rest of Europe market size and forecast, by cancer type223
8.3.2.6.4.Rest of Europe market size and forecast, by application224
8.3.3.Europe market size and forecast, by profiling technologies225
8.3.4.Europe market size and forecast, by biomolecules226
8.3.5.Europe market size and forecast, by cancer type227
8.3.6.Europe market size and forecast, by application228
8.4.Asia-Pacific229
8.4.1.Key market trends and opportunities229
8.4.2.Market analysis by country230
8.4.2.1.Japan231
8.4.2.1.1.Japan market size and forecast, by profiling technologies231
8.4.2.1.2.Japan market size and forecast, by biomolecules233
8.4.2.1.3.Japan market size and forecast, by cancer type234
8.4.2.1.4.Japan market size and forecast, by application235
8.4.2.2.China236
8.4.2.2.1.China market size and forecast, by profiling technologies236
8.4.2.2.2.China market size and forecast, by biomolecules237
8.4.2.2.3.China market size and forecast, by cancer type238
8.4.2.2.4.China market size and forecast, by application239
8.4.2.3.Australia240
8.4.2.3.1.Australia market size and forecast, by profiling technologies240
8.4.2.3.2.Australia market size and forecast, by biomolecules242
8.4.2.3.3.Australia market size and forecast, by cancer type243
8.4.2.3.4.Australia market size and forecast, by application244
8.4.2.4.India245
8.4.2.4.1.India market size and forecast, by profiling technologies245
8.4.2.4.2.India market size and forecast, by biomolecules246
8.4.2.4.3.India market size and forecast, by cancer type247
8.4.2.4.4.India market size and forecast, by application248
8.4.2.5.Rest of Asia-Pacific249
8.4.2.5.1.Rest of Asia-Pacific market size and forecast, by profiling technologies249
8.4.2.5.2.Rest of Asia-Pacific market size and forecast, by biomolecules250
8.4.2.5.3.Rest of Asia-Pacific market size and forecast, by cancer type251
8.4.2.5.4.Rest of Asia-Pacific market size and forecast, by application252
8.4.3.Asia-Pacific market size and forecast, by profiling technologies253
8.4.4.Asia-Pacific market size and forecast, by biomolecules254
8.4.5.Asia-Pacific market size and forecast, by cancer type255
8.4.6.Asia-Pacific market size and forecast, by application256
8.5.LAMEA257
8.5.1.Key market trends and opportunities257
8.5.2.Market analysis by country258
8.5.2.1.Brazil260
8.5.2.1.1.Brazil market size and forecast, by profiling technologies260
8.5.2.1.2.Brazil market size and forecast, by biomolecules261
8.5.2.1.3.Brazil market size and forecast, by cancer type262
8.5.2.1.4.Brazil market size and forecast, by application263
8.5.2.2.Saudi Arabia264
8.5.2.2.1.Saudi Arabia market size and forecast, by profiling technologies264
8.5.2.2.2.Saudi Arabia market size and forecast, by biomolecules266
8.5.2.2.3.Saudi Arabia market size and forecast, by cancer type267
8.5.2.2.4.Saudi Arabia market size and forecast, by application268
8.5.2.3.United Arab Emirates269
8.5.2.3.1.United Arab Emirates market size and forecast, by profiling technologies269
8.5.2.3.2.United Arab Emirates market size and forecast, by biomolecules270
8.5.2.3.3.United Arab Emirates market size and forecast, by cancer type271
8.5.2.3.4.United Arab Emirates market size and forecast, by application272
8.5.2.4.Rest of LAMEA273
8.5.2.4.1.Rest of LAMEA market size and forecast, by profiling technologies273
8.5.2.4.2.Rest of LAMEA market size and forecast, by biomolecules275
8.5.2.4.3.Rest of LAMEA market size and forecast, by cancer type276
8.5.2.4.4.Rest of LAMEA market size and forecast, by application277
8.5.3.LAMEA market size and forecast, by profiling technologies278
8.5.4.LAMEA market size and forecast, by biomolecules279
8.5.5.LAMEA market size and forecast, by cancer type280
8.5.6.LAMEA market size and forecast, by application281
CHAPTER 9:COMPANY PROFILES282
9.1.Abbott Laboratories282
9.1.1.Company overview282
9.1.2.Company snapshot282
9.1.3.Operating business segments283
9.1.4.Product portfolio283
9.1.5.Business performance285
9.2.BIO-RAD LABORATORIES, INC.287
9.2.1.Company overview287
9.2.2.Company snapshot288
9.2.3.Operating business segments289
9.2.4.Product Portfolio289
9.2.5.Business performance290
9.3.Bristol-Myers Squibb Company292
9.3.1.Company overview292
9.3.2.Company snapshot293
9.3.3.Operating business segments293
9.3.4.Product portfolio294
9.3.5.Business performance294
9.3.6.Key strategic moves and developments296
9.5.EXACT SCIENCES CORPORATION297
9.5.1.Company overview297
9.5.2.Company snapshot297
9.5.3.Operating business segments298
9.5.4.Product portfolio298
9.5.5.Business performance299
9.5.6.Key strategic moves and developments299
9.6.F. HOFFMANN-LA ROCHE LTD.301
9.6.1.Company overview301
9.6.2.Company snapshot301
9.6.3.Operating business segments302
9.6.4.Product portfolio303
9.6.5.Business performance304
305
9.6.6.Key strategic moves and developments306
9.7.Merck KGaA307
9.7.1.Company overview307
9.7.2.Company snapshot307
9.7.3.Operating business segments308
9.7.4.Product portfolio308
9.7.5.Business performance309
9.7.6.Key strategic moves and developments311
9.8.PERKINELMER, INC.312
9.8.1.Company overview312
9.8.2.Company snapshot312
9.8.3.Operating business segments313
9.8.4.Product portfolio314
9.8.5.Business performance315
9.8.6.Key strategic moves and developments317
9.9.QIAGEN N.V.318
9.9.1.Company overview318
9.9.2.Company snapshot318
9.9.3.Operating business segments319
9.9.4.Product portfolio320
9.9.5.Business performance320
9.9.6.Key strategic moves and developments322
9.10.Siemens AG323
9.10.1.Company overview323
9.10.2.Company snapshot324
9.10.3.Operating business segments324
9.10.4.Product portfolio325
9.10.5.Business performance326
9.11.THERMO FISHER SCIENTIFIC, INC.328
9.11.1.Company overview328
9.11.2.Company snapshot328
9.11.3.Operating business segments329
9.11.4.Product portfolio331
9.11.5.Business performance332
9.11.6.Key strategic moves and developments334
1.1.Report description40
1.2.Key benefits for stakeholders41
1.3.Key market segments43
1.3.1.List of key players profiled in the report45
1.4.Research methodology46
1.4.1.Secondary research48
1.4.2.Primary research48
1.4.3.Analyst tools and models49
CHAPTER 2:EXECUTIVE SUMMARY50
2.1.Key findings of the study52
2.2.CXO perspective53
CHAPTER 3:MARKET OVERVIEW54
3.1.Market definition and scope54
3.2.Biomarker Diagnosis vs. Conventional Diagnosis56
3.3.Key findings57
3.3.1.Top investment pockets57
3.4.Porter's five forces analysis59
3.4.1.Bargaining power of buyers59
3.4.2.Bargaining power of suppliers60
3.4.3.Thereat of new entrants61
3.4.4.Threat of substitutes62
3.4.5.Intensity of competitive rivalry63
3.5.Top player positioning, 201964
3.6.Market dynamics65
3.6.1.Drivers65
3.6.1.1.Rise in incidence and prevalence of various cancer types65
3.6.1.2.Growth in importance of biological and targeted drug therapies67
3.6.1.3.Increase in acquisitions and collaborations69
3.6.1.4.Increase in technological advancements70
3.6.1.5.High accuracy and reliability70
3.6.1.6.Rise in investment from government, public, and private sectors70
3.6.1.7.Increase in clinical trials71
3.6.1.8.Growth in popularity of personalized medicine and companion diagnostics71
3.6.2.Restraint72
3.6.2.1.High cost of drug development and threat of failure72
3.6.2.2.Unregulated government regulation and reimbursement policies72
3.6.2.3.Adverse effects of cancer drug therapy73
3.6.3.Opportunity73
3.6.3.1.Advancement of cancer drugs research73
3.6.3.2.Increased focus towards advanced treatment protocols74
3.6.3.3.Significant unmet need in cancer diagnosis74
3.6.3.4.Increased awareness to reduce healthcare costs74
3.6.3.5.Opportunities in emerging economies75
3.6.4.Impact Analyses75
3.7.PATENT ANALYSIS76
3.8.Clinical Trials Analysis78
CHAPTER 4:CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY79
4.1.Overview79
4.1.1.Market size and forecast, by profiling technologies80
4.2.OMIC TECHNOLOGIES82
4.2.1.Key market trends and growth opportunities82
4.2.2.Market size and forecast, by region83
4.2.3.Market analysis, by country84
4.2.4.Market size and forecast, by type85
4.2.5.Genomics86
4.2.5.1.Market Size and forecast87
4.2.5.2.Next Generation Sequencing (NGS)88
4.2.5.3.Microarray89
4.2.5.4.Polymerase chain reaction (PCR)89
4.2.6.Proteomics90
4.2.6.1.Market size and forecast90
4.2.6.2.Mass spectrometry92
4.2.6.3.2D gel electrophoresis92
4.2.6.4.Protein microarray technology93
4.2.6.5.Antibody array technology94
4.2.6.6.Peptide array technology94
4.2.7.Other omic technologies95
4.2.7.1.Market size and forecast95
4.2.7.2.Metabolomics96
4.2.7.3.Glycomics97
4.3.IMAGING TECHNOLOGIES97
4.3.1.Key market trends and growth opportunities97
4.3.2.Market size and forecast, by region98
4.3.3.Market analysis, by countries99
4.3.4.Market size and forecast, by type100
4.3.5.Magnetic resonance imaging (MRI)101
4.3.5.1.Market size and forecast102
4.3.6.Positron emission tomography (PET)103
4.3.6.1.Market size and forecast103
4.3.7.Computed tomography (CT)104
4.3.7.1.Market size and forecast105
4.3.8.Mammography105
4.3.8.1.Market size and forecast106
4.3.9.Ultrasound107
4.3.9.1.Market size and forecast107
4.4.IMMUNOASSAYS108
4.4.1.Key market trends and growth opportunities109
4.4.2.Market size and forecast, by region109
4.4.3.Market analysis, by country110
4.4.4.Market size and forecast, by type112
4.4.5.Immunohistochemistry (IHC) tests113
4.4.5.1.Market size and forecast113
4.4.6.Enzyme-linked immunosorbent assay (ELISA)114
4.4.6.1.Market size and forecast114
4.4.7.Flow cytometry115
4.4.7.1.Market size and forecast116
4.5.CYTOGENETICS-BASED TESTS117
4.5.1.Key market trends and growth opportunities117
4.5.2.Market size and forecast, by region118
4.5.3.Market analysis, by country119
4.5.4.Market size and forecast, by type120
4.5.5.In-situ hybridization121
4.5.5.1.Market size and forecast121
4.5.6.Others122
4.5.6.1.Market size and forecast122
CHAPTER 5:CANCER BIOMARKERS MARKET, BY BIOMOLECULE124
5.1.Overview124
5.1.1.Market size and forecast125
5.2.Genetic Biomarkers126
5.2.1.Market size and forecast, by region128
5.2.2.Market analysis, by country129
5.3.Protein Biomarkers130
5.3.1.Market size and forecast, by region130
5.3.2.Market analysis, by country131
5.4.Glyco-Biomarkers133
5.4.1.Market size and forecast, by region134
5.4.2.Market analysis, by country135@CHAPTER 6:CANCER BIOSENSORS MARKET, BY CANCER TYPE136
6.1.Overview136
6.1.1.Market size and forecast137
6.2.Breast Cancer138
6.2.1.Market size and forecast, by region139
6.2.2.Market analysis, by country140
6.3.Lung Cancer141
6.3.1.Market size and forecast, by region141
6.3.2.Market analysis, by country142
6.4.Colorectal cancer143
6.4.1.Market size and forecast, by region144
6.4.2.Market analysis, by country145
6.5.Prostate cancer146
6.5.1.Market size and forecast, by region147
6.5.2.Market analysis, by country148
6.6.Stomach cancer149
6.6.1.Market size and forecast, by region150
6.6.2.Market analysis, by country150
6.7.Others152
6.7.1.Market size and forecast, by region152
6.7.2.Market analysis, by country153
CHAPTER 7:CANCER BIOMARKER MARKET, BY APPLICATION155
7.1.Overview155
7.1.1.Market size and forecast155
7.2.Diagnostics157
7.2.1.Market size and forecast, by region158
7.2.2.Market analysis, by country159
7.3.Drug Discovery and Development160
7.3.1.Market size and forecast, by region161
7.3.2.Market analysis, by country162
7.4.Prognostics163
7.4.1.Market size and forecast, by region164
7.4.2.Market analysis, by country164
7.5.Risk Assessment166
7.5.1.Market size and forecast, by region166
7.5.2.Market analysis, by country167
7.6.Others168
7.6.1.Market size and forecast, by region169
7.6.2.Market analysis, by country170
CHAPTER 8:CANCER BIOMARKERS MARKET, BY REGION172
8.1.Overview172
8.1.1.Market size and forecast173
8.2.North America174
8.2.1.Key market trends and opportunities174
8.2.2.Market analysis by country175
8.2.2.1.U.S.176
8.2.2.1.1.U.S. market size and forecast, by profiling technologies176
8.2.2.1.2.U.S. market size and forecast, by biomolecules177
8.2.2.1.3.U.S. market size and forecast, by cancer type178
8.2.2.1.4.U.S. market size and forecast, by application179
8.2.2.2.Canada180
8.2.2.2.1.Canada market size and forecast, by profiling technologies180
8.2.2.2.2.Canada market size and forecast, by biomolecules182
8.2.2.2.3.Canada market size and forecast, by cancer type183
8.2.2.2.4.Canada market size and forecast, by application184
8.2.2.3.Mexico185
8.2.2.3.1.Mexico market size and forecast, by profiling technologies185
8.2.2.3.2.Mexico market size and forecast, by biomolecules187
8.2.2.3.3.Mexico market size and forecast, by cancer type188
8.2.2.3.4.Mexico market size and forecast, by application189
8.2.3.North America market size and forecast, by profiling technologies190
8.2.4.North America market size and forecast, by biomolecules191
8.2.5.North America market size and forecast, by cancer type192
8.2.6.North America market size and forecast, by application193
8.3.Europe194
8.3.1.Key market trends and opportunities194
8.3.2.Market analysis by country195
8.3.2.1.Germany197
8.3.2.1.1.Germany market size and forecast, by profiling technologies197
8.3.2.1.2.Germany market size and forecast, by biomolecules199
8.3.2.1.3.Germany market size and forecast, by cancer type200
8.3.2.1.4.Germany market size and forecast, by application201
8.3.2.2.France202
8.3.2.2.1.France market size and forecast, by profiling technologies202
8.3.2.2.2.France market size and forecast, by biomolecules204
8.3.2.2.3.France market size and forecast, by cancer type205
8.3.2.2.4.France market size and forecast, by application206
8.3.2.3.UK207
8.3.2.3.1.UK market size and forecast, by profiling technologies207
8.3.2.3.2.UK market size and forecast, by biomolecules208
8.3.2.3.3.UK market size and forecast, by cancer type209
8.3.2.3.4.UK market size and forecast, by application210
8.3.2.4.Italy211
8.3.2.4.1.Italy market size and forecast, by profiling technologies211
8.3.2.4.2.Italy market size and forecast, by biomolecules212
8.3.2.4.3.Italy market size and forecast, by cancer type213
8.3.2.4.4.Italy market size and forecast, by application214
8.3.2.5.Russia215
8.3.2.5.1.Russia market size and forecast, by profiling technologies215
8.3.2.5.2.Russia market size and forecast, by biomolecules217
8.3.2.5.3.Russia market size and forecast, by cancer type218
8.3.2.5.4.Russia market size and forecast, by application219
8.3.2.6.Rest of Europe220
8.3.2.6.1.Rest of Europe market size and forecast, by profiling technologies220
8.3.2.6.2.Rest of Europe market size and forecast, by biomolecules222
8.3.2.6.3.Rest of Europe market size and forecast, by cancer type223
8.3.2.6.4.Rest of Europe market size and forecast, by application224
8.3.3.Europe market size and forecast, by profiling technologies225
8.3.4.Europe market size and forecast, by biomolecules226
8.3.5.Europe market size and forecast, by cancer type227
8.3.6.Europe market size and forecast, by application228
8.4.Asia-Pacific229
8.4.1.Key market trends and opportunities229
8.4.2.Market analysis by country230
8.4.2.1.Japan231
8.4.2.1.1.Japan market size and forecast, by profiling technologies231
8.4.2.1.2.Japan market size and forecast, by biomolecules233
8.4.2.1.3.Japan market size and forecast, by cancer type234
8.4.2.1.4.Japan market size and forecast, by application235
8.4.2.2.China236
8.4.2.2.1.China market size and forecast, by profiling technologies236
8.4.2.2.2.China market size and forecast, by biomolecules237
8.4.2.2.3.China market size and forecast, by cancer type238
8.4.2.2.4.China market size and forecast, by application239
8.4.2.3.Australia240
8.4.2.3.1.Australia market size and forecast, by profiling technologies240
8.4.2.3.2.Australia market size and forecast, by biomolecules242
8.4.2.3.3.Australia market size and forecast, by cancer type243
8.4.2.3.4.Australia market size and forecast, by application244
8.4.2.4.India245
8.4.2.4.1.India market size and forecast, by profiling technologies245
8.4.2.4.2.India market size and forecast, by biomolecules246
8.4.2.4.3.India market size and forecast, by cancer type247
8.4.2.4.4.India market size and forecast, by application248
8.4.2.5.Rest of Asia-Pacific249
8.4.2.5.1.Rest of Asia-Pacific market size and forecast, by profiling technologies249
8.4.2.5.2.Rest of Asia-Pacific market size and forecast, by biomolecules250
8.4.2.5.3.Rest of Asia-Pacific market size and forecast, by cancer type251
8.4.2.5.4.Rest of Asia-Pacific market size and forecast, by application252
8.4.3.Asia-Pacific market size and forecast, by profiling technologies253
8.4.4.Asia-Pacific market size and forecast, by biomolecules254
8.4.5.Asia-Pacific market size and forecast, by cancer type255
8.4.6.Asia-Pacific market size and forecast, by application256
8.5.LAMEA257
8.5.1.Key market trends and opportunities257
8.5.2.Market analysis by country258
8.5.2.1.Brazil260
8.5.2.1.1.Brazil market size and forecast, by profiling technologies260
8.5.2.1.2.Brazil market size and forecast, by biomolecules261
8.5.2.1.3.Brazil market size and forecast, by cancer type262
8.5.2.1.4.Brazil market size and forecast, by application263
8.5.2.2.Saudi Arabia264
8.5.2.2.1.Saudi Arabia market size and forecast, by profiling technologies264
8.5.2.2.2.Saudi Arabia market size and forecast, by biomolecules266
8.5.2.2.3.Saudi Arabia market size and forecast, by cancer type267
8.5.2.2.4.Saudi Arabia market size and forecast, by application268
8.5.2.3.United Arab Emirates269
8.5.2.3.1.United Arab Emirates market size and forecast, by profiling technologies269
8.5.2.3.2.United Arab Emirates market size and forecast, by biomolecules270
8.5.2.3.3.United Arab Emirates market size and forecast, by cancer type271
8.5.2.3.4.United Arab Emirates market size and forecast, by application272
8.5.2.4.Rest of LAMEA273
8.5.2.4.1.Rest of LAMEA market size and forecast, by profiling technologies273
8.5.2.4.2.Rest of LAMEA market size and forecast, by biomolecules275
8.5.2.4.3.Rest of LAMEA market size and forecast, by cancer type276
8.5.2.4.4.Rest of LAMEA market size and forecast, by application277
8.5.3.LAMEA market size and forecast, by profiling technologies278
8.5.4.LAMEA market size and forecast, by biomolecules279
8.5.5.LAMEA market size and forecast, by cancer type280
8.5.6.LAMEA market size and forecast, by application281
CHAPTER 9:COMPANY PROFILES282
9.1.Abbott Laboratories282
9.1.1.Company overview282
9.1.2.Company snapshot282
9.1.3.Operating business segments283
9.1.4.Product portfolio283
9.1.5.Business performance285
9.2.BIO-RAD LABORATORIES, INC.287
9.2.1.Company overview287
9.2.2.Company snapshot288
9.2.3.Operating business segments289
9.2.4.Product Portfolio289
9.2.5.Business performance290
9.3.Bristol-Myers Squibb Company292
9.3.1.Company overview292
9.3.2.Company snapshot293
9.3.3.Operating business segments293
9.3.4.Product portfolio294
9.3.5.Business performance294
9.3.6.Key strategic moves and developments296
9.5.EXACT SCIENCES CORPORATION297
9.5.1.Company overview297
9.5.2.Company snapshot297
9.5.3.Operating business segments298
9.5.4.Product portfolio298
9.5.5.Business performance299
9.5.6.Key strategic moves and developments299
9.6.F. HOFFMANN-LA ROCHE LTD.301
9.6.1.Company overview301
9.6.2.Company snapshot301
9.6.3.Operating business segments302
9.6.4.Product portfolio303
9.6.5.Business performance304
305
9.6.6.Key strategic moves and developments306
9.7.Merck KGaA307
9.7.1.Company overview307
9.7.2.Company snapshot307
9.7.3.Operating business segments308
9.7.4.Product portfolio308
9.7.5.Business performance309
9.7.6.Key strategic moves and developments311
9.8.PERKINELMER, INC.312
9.8.1.Company overview312
9.8.2.Company snapshot312
9.8.3.Operating business segments313
9.8.4.Product portfolio314
9.8.5.Business performance315
9.8.6.Key strategic moves and developments317
9.9.QIAGEN N.V.318
9.9.1.Company overview318
9.9.2.Company snapshot318
9.9.3.Operating business segments319
9.9.4.Product portfolio320
9.9.5.Business performance320
9.9.6.Key strategic moves and developments322
9.10.Siemens AG323
9.10.1.Company overview323
9.10.2.Company snapshot324
9.10.3.Operating business segments324
9.10.4.Product portfolio325
9.10.5.Business performance326
9.11.THERMO FISHER SCIENTIFIC, INC.328
9.11.1.Company overview328
9.11.2.Company snapshot328
9.11.3.Operating business segments329
9.11.4.Product portfolio331
9.11.5.Business performance332
9.11.6.Key strategic moves and developments334
LIST OF TABLES
TABLE 01.CONVENTIONAL DIAGNOSTICS VS. DIAGNOSTIC BIOMARKER TECHNIQUES60
TABLE 02.GLOBAL CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGIES, 2019–2027 ($MILLION)86
TABLE 03.OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)89
TABLE 04.OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)92
TABLE 05.GENOMICS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)93
TABLE 06.PROTEOMICS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)97
TABLE 07.OTHER OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)101
TABLE 08.IMAGING TECHNOLOGIES CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)105
TABLE 09.IMAGING TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)107
TABLE 10.IMMUNOASSAYS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)116
TABLE 11.IMMUNOASSAYS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)118
TABLE 12.CYTOGENETICS-BASED TESTS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)124
TABLE 13.CYTOGENETICS-BASED TESTS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)127
TABLE 14.GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE, BY BIOMOLECULE, 2019–2027 ($MILLION)131
TABLE 15.GENETIC BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)134
TABLE 16.PROTEIN BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)137
TABLE 17.GLYCO-BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)140
TABLE 18.GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2019–2027 ($MILLION)144
TABLE 19.BREAST CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)146
TABLE 20.LUNG CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)149
TABLE 21.COLORECTAL CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)151
TABLE 22.PROSTATE CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)154
TABLE 23.STOMACH CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)157
TABLE 24.OTHERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)160
TABLE 25.GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION, 2019–2027 ($MILLION)163
TABLE 26.DIAGNOSTICS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)165
TABLE 27.DRUG DISCOVERY AND DEVELOPMENT CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)169
TABLE 28.PROGNOSTICS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)171
TABLE 29.RISK ASSESSMENT CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)174
TABLE 30.OTHERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)177
TABLE 31.CANCER BIOMARKERS MARKET, BY REGION, 2018-2026 ($MILLION)180
TABLE 32.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)182
TABLE 33.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)183
TABLE 34.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)185
TABLE 35.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)186
TABLE 36.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)187
TABLE 37.CANADA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)188
TABLE 38.CANADA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)190
TABLE 39.CANADA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)191
TABLE 40.CANADA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)192
TABLE 41.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)193
TABLE 42.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)194
TABLE 43.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)195
TABLE 44.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)196
TABLE 45.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)197
TABLE 46.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)198
TABLE 47.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)199
TABLE 48.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)200
TABLE 49.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)202
TABLE 50.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)204
TABLE 51.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)206
TABLE 52.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)207
TABLE 53.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)208
TABLE 54.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)209
TABLE 55.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)210
TABLE 56.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)211
TABLE 57.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)212
TABLE 58.UK CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)213
TABLE 59.UK CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)214
TABLE 60.UK CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)215
TABLE 61.UK CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)216
TABLE 62.ITALY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)217
TABLE 63.ITALY CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)218
TABLE 64.ITALY CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)219
TABLE 65.ITALY CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)220
TABLE 66.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)221
TABLE 67.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)222
TABLE 68.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)223
TABLE 69.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)224
TABLE 70.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)225
TABLE 71.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)226
TABLE 72.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)227
TABLE 73.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)228
TABLE 74.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)229
TABLE 75.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)230
TABLE 76.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)231
TABLE 77.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)232
TABLE 78.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)235
TABLE 79.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)236
TABLE 80.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)237
TABLE 81.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)238
TABLE 82.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)239
TABLE 83.CHINA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)240
TABLE 84.CHINA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)241
TABLE 85.CHINA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)242
TABLE 86.CHINA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)243
TABLE 87.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)244
TABLE 88.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)245
TABLE 89.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)246
TABLE 90.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)247
TABLE 91.INDIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)248
TABLE 92.INDIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)249
TABLE 93.INDIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)250
TABLE 94.INDIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)251
TABLE 95.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)252
TABLE 96.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)253
TABLE 97.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)254
TABLE 98.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)255
TABLE 99.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)256
TABLE 100.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)257
TABLE 101.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)258
TABLE 102.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)259
TABLE 103.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)261
TABLE 104.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)263
TABLE 105.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)264
TABLE 106.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)265
TABLE 107.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)266
TABLE 108.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)267
TABLE 109.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)269
TABLE 110.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)270
TABLE 111.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)271
TABLE 112.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)272
TABLE 113.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)273
TABLE 114.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)274
TABLE 115.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)275
TABLE 116.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)276
TABLE 117.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)278
TABLE 118.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)279
TABLE 119.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)280
TABLE 120.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)281
TABLE 121.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)282
TABLE 122.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)283
TABLE 123.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)284
TABLE 124.ABBOTT: COMPANY SNAPSHOT285
TABLE 125.ABBOTT: OPERATING SEGMENTS286
TABLE 126.ABBOTT: PRODUCT PORTFOLIO287
TABLE 127.BIO-RAD: COMPANY SNAPSHOT291
TABLE 128.BIO-RAD: OPERATING SEGMENTS292
TABLE 129.BIO-RAD: PRODUCT PORTFOLIO292
TABLE 130.BMS: COMPANY SNAPSHOT296
TABLE 131.BMS: PRODUCT PORTFOLIO297
TABLE 132.EXACT SCIENCES: COMPANY SNAPSHOT300
TABLE 133.EXACT SCIEN
TABLE 01.CONVENTIONAL DIAGNOSTICS VS. DIAGNOSTIC BIOMARKER TECHNIQUES60
TABLE 02.GLOBAL CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGIES, 2019–2027 ($MILLION)86
TABLE 03.OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)89
TABLE 04.OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)92
TABLE 05.GENOMICS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)93
TABLE 06.PROTEOMICS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)97
TABLE 07.OTHER OMIC TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)101
TABLE 08.IMAGING TECHNOLOGIES CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)105
TABLE 09.IMAGING TECHNOLOGIES CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)107
TABLE 10.IMMUNOASSAYS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)116
TABLE 11.IMMUNOASSAYS CANCER BIOMARKERS MARKET, BY TYPE, 2019–2027 ($MILLION)118
TABLE 12.CYTOGENETICS-BASED TESTS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)124
TABLE 13.CYTOGENETICS-BASED TESTS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)127
TABLE 14.GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE, BY BIOMOLECULE, 2019–2027 ($MILLION)131
TABLE 15.GENETIC BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)134
TABLE 16.PROTEIN BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)137
TABLE 17.GLYCO-BIOMARKERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)140
TABLE 18.GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2019–2027 ($MILLION)144
TABLE 19.BREAST CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)146
TABLE 20.LUNG CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)149
TABLE 21.COLORECTAL CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)151
TABLE 22.PROSTATE CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)154
TABLE 23.STOMACH CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)157
TABLE 24.OTHERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)160
TABLE 25.GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION, 2019–2027 ($MILLION)163
TABLE 26.DIAGNOSTICS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)165
TABLE 27.DRUG DISCOVERY AND DEVELOPMENT CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)169
TABLE 28.PROGNOSTICS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)171
TABLE 29.RISK ASSESSMENT CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)174
TABLE 30.OTHERS CANCER BIOMARKERS MARKET, BY REGION, 2019–2027 ($MILLION)177
TABLE 31.CANCER BIOMARKERS MARKET, BY REGION, 2018-2026 ($MILLION)180
TABLE 32.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)182
TABLE 33.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)183
TABLE 34.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)185
TABLE 35.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)186
TABLE 36.THE U.S. CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)187
TABLE 37.CANADA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)188
TABLE 38.CANADA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)190
TABLE 39.CANADA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)191
TABLE 40.CANADA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)192
TABLE 41.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)193
TABLE 42.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)194
TABLE 43.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)195
TABLE 44.MEXICO CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)196
TABLE 45.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)197
TABLE 46.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)198
TABLE 47.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)199
TABLE 48.NORTH AMERICA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)200
TABLE 49.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)202
TABLE 50.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)204
TABLE 51.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)206
TABLE 52.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)207
TABLE 53.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)208
TABLE 54.GERMANY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)209
TABLE 55.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)210
TABLE 56.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)211
TABLE 57.FRANCE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)212
TABLE 58.UK CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)213
TABLE 59.UK CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)214
TABLE 60.UK CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)215
TABLE 61.UK CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)216
TABLE 62.ITALY CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)217
TABLE 63.ITALY CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)218
TABLE 64.ITALY CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)219
TABLE 65.ITALY CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)220
TABLE 66.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)221
TABLE 67.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)222
TABLE 68.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)223
TABLE 69.RUSSIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)224
TABLE 70.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)225
TABLE 71.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)226
TABLE 72.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)227
TABLE 73.REST OF EUROPE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)228
TABLE 74.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)229
TABLE 75.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)230
TABLE 76.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)231
TABLE 77.EUROPE CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)232
TABLE 78.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)235
TABLE 79.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)236
TABLE 80.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)237
TABLE 81.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)238
TABLE 82.JAPAN CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)239
TABLE 83.CHINA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)240
TABLE 84.CHINA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)241
TABLE 85.CHINA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)242
TABLE 86.CHINA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)243
TABLE 87.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)244
TABLE 88.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)245
TABLE 89.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)246
TABLE 90.AUSTRALIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)247
TABLE 91.INDIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)248
TABLE 92.INDIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)249
TABLE 93.INDIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)250
TABLE 94.INDIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)251
TABLE 95.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)252
TABLE 96.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)253
TABLE 97.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)254
TABLE 98.REST OF ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)255
TABLE 99.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)256
TABLE 100.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)257
TABLE 101.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)258
TABLE 102.ASIA-PACIFIC CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)259
TABLE 103.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY COUNTRY 2019–2026 ($MILLION)261
TABLE 104.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)263
TABLE 105.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)264
TABLE 106.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)265
TABLE 107.BRAZIL CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)266
TABLE 108.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)267
TABLE 109.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)269
TABLE 110.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)270
TABLE 111.SAUDI ARABIA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)271
TABLE 112.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)272
TABLE 113.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)273
TABLE 114.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)274
TABLE 115.UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)275
TABLE 116.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)276
TABLE 117.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)278
TABLE 118.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)279
TABLE 119.REST OF LAMEA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)280
TABLE 120.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY PROFILING TECHNOLOGIES 2019–2027 ($MILLION)281
TABLE 121.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY BIOMOLECULES 2019–2027 ($MILLION)282
TABLE 122.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY CANCER TYPE 2019–2027 ($MILLION)283
TABLE 123.LAMEA CANCER BIOMARKERS MARKET REVENUE, BY APPLICATION 2019–2027 ($MILLION)284
TABLE 124.ABBOTT: COMPANY SNAPSHOT285
TABLE 125.ABBOTT: OPERATING SEGMENTS286
TABLE 126.ABBOTT: PRODUCT PORTFOLIO287
TABLE 127.BIO-RAD: COMPANY SNAPSHOT291
TABLE 128.BIO-RAD: OPERATING SEGMENTS292
TABLE 129.BIO-RAD: PRODUCT PORTFOLIO292
TABLE 130.BMS: COMPANY SNAPSHOT296
TABLE 131.BMS: PRODUCT PORTFOLIO297
TABLE 132.EXACT SCIENCES: COMPANY SNAPSHOT300
TABLE 133.EXACT SCIEN
